Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma Group (MREO) Other Non-Current Liabilities: 2020-2025

Historic Other Non-Current Liabilities for Mereo BioPharma Group (MREO) over the last 2 years, with Sep 2025 value amounting to $652,000.

  • Mereo BioPharma Group's Other Non-Current Liabilities fell 37.31% to $652,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $652,000, marking a year-over-year decrease of 37.31%. This contributed to the annual value of $821,000 for FY2024, which is 7.46% up from last year.
  • According to the latest figures from Q3 2025, Mereo BioPharma Group's Other Non-Current Liabilities is $652,000, which was up 19.63% from $545,000 recorded in Q2 2025.
  • In the past 5 years, Mereo BioPharma Group's Other Non-Current Liabilities ranged from a high of $47.5 million in Q2 2021 and a low of $8,694 during Q2 2022.
  • Moreover, its 3-year median value for Other Non-Current Liabilities was $792,500 (2023), whereas its average is $752,625.
  • As far as peak fluctuations go, Mereo BioPharma Group's Other Non-Current Liabilities tumbled by 99.98% in 2022, and later rose by 7.46% in 2024.
  • Mereo BioPharma Group's Other Non-Current Liabilities (Quarterly) stood at $11.2 million in 2021, then slumped by 92.27% to $869,000 in 2022, then dropped by 12.08% to $764,000 in 2023, then climbed by 7.46% to $821,000 in 2024, then crashed by 37.31% to $652,000 in 2025.
  • Its last three reported values are $652,000 in Q3 2025, $545,000 for Q2 2025, and $419,000 during Q1 2025.